$MD

Young Sylvia Jean sold (to issuer) $492K of MD

Young Sylvia Jean sold (to issuer) 18,500 shares of Pediatrix Medical Group, Inc. (MD) at $26.62 ($0.49M total) on 2026-08-14.

Original reporting
SEC EDGAR · Young Sylvia Jean
Published Aug 18, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MD
Neutral
high confidence
Mentioned
$MD
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDNeutralLow
01

Why it matters

The disclosed event is an insider sale to the issuer at a stated price, with no additional company-specific news (earnings, guidance, contracts, or regulatory actions) included.

02

Market read

Traders may note insider selling, but the filing alone does not provide a new fundamental catalyst.

03

What to watch

The article does not state whether the transaction was part of a broader pattern, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-08-18, covering a sale dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for Pediatrix Medical Group, Inc.

Company-level read

Ticker impact

$MDNeutralHigh confidence
Context

Pediatrix Medical Group director Young Sylvia Jean sold 18,500 shares to the issuer at $26.62 for about $492,470, per Form 4.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and small.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with no 10b5-1 plan and no accompanying company guidance, deal, or regulatory action in the text.

Market effects

No sector read-through is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale is to the issuer and may reflect liquidity or plan mechanics rather than bearish expectations.

Key entities

  • Pediatrix Medical Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Young Sylvia Jean

    Director who sold 18,500 shares to the issuer on 2026-08-14.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDMedAI 8/10

Pediatrix Medical Group (MD) Q2 2026 Earnings Call Transcript

Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.

$MDMed

Pediatrix Medical Group, Inc. (MD): Results of Operations and Financial Condition

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 4, 2026 - Pediatrix Medical G

$MDMed

Pediatrix Medical Group, Inc. (MD): Results of Operations and Financial Condition

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Provides Second Quarter Update FORT LAUDERDALE, Fl

$MDHighAI 9/10

Does Pediatrix Medical Group (MD) Stock Look Better After Q1 Report?

Pediatrix Medical Group (NYSE:MD) reported Q1 2026 results on May 5. Revenue rose to $476.2 million from $458.4 million a year earlier, beating the $465.7 million analyst estimate, according to the company. Adjusted EBITDA increased to $58.2 million from $49.2 million. Adjusted EPS was $0.44 vs. $0.33 a year ago, above the $0.38 estimate. The company expects full-year 2026 adjusted EBITDA of $280–$300 million.